Apport du PSA dans la prise en charge sur près de 20 ans d’un patient atteint d’un cancer de la prostate
作者： J.-P. Basuyau , F. Thuillier
DOI: 10.1016/J.IMMBIO.2009.02.001
关键词:
摘要: Summary The question of the use PSA in therapeutic management prostate cancers settles France a pointed enough way to have brought French Association Urology (AFU) and Society Clinical Biology (SFBC) realize at end 2008 survey on subject. case Doctor H., 66 years, making measure its conformance with what will become “organized individual screening” is particularly illustrative impact which this dosage can throughout disease.
elsevier.com
sci-hub.se 参考文章(5)
A. Benchikh El Fegoun, A. Villers, J.-L. Moreau, P. Richaud, X. Rebillard, P. Beuzeboc, PSA et suivi après traitement du cancer de la prostate Progres En Urologie. ,vol. 18, pp. 137- 144 ,(2008) , 10.1016/J.PUROL.2007.12.010
Xavier Rebillard, François Grima, Alain Ruffion, Temps de doublement du PSA et son calcul Progres En Urologie. ,vol. 15, pp. 1035- 1041 ,(2005)
Yvonne Fulla, Michèle Noel, Gaëlle Le Brun, Optimisation de l’utilisation du PSA Médecine Nucléaire. ,vol. 32, pp. 31- 40 ,(2008) , 10.1016/J.MEDNUC.2007.11.004
Catharine M Sturgeon, Michael J Duffy, Ulf-Håkan Stenman, Hans Lilja, Nils Brünner, Daniel W Chan, Richard Babaian, Robert C Bast, Barry Dowell, Francisco J Esteva, Caj Haglund, Nadia Harbeck, Daniel F Hayes, Mads Holten-Andersen, George G Klee, Rolf Lamerz, Leendert H Looijenga, Rafael Molina, Hans Jørgen Nielsen, Harry Rittenhouse, Axel Semjonow, Ie-Ming Shih, Paul Sibley, György Sölétormos, Carsten Stephan, Lori Sokoll, Barry R Hoffman, Eleftherios P Diamandis, National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clinical Chemistry. ,vol. 54, ,(2008) , 10.1373/CLINCHEM.2008.105601
Jean-Léon Lagrange, Stéphane Guerif, [T1-T2 prostate cancer: treatment by radiation therapy]. Bulletin Du Cancer. ,vol. 94, pp. 5- 14 ,(2007) , 10.1684/BDC.2007.0243